VRAX Stock Analysis: Buy, Sell, or Hold?
VRAX - Virax Biolabs Group Limited Ordinary Shares
$3.13
0.39 (14.23%)
▲
5d:
+2218.52%
30d:
+1347.06%
90d:
+1480.81%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 01, 2026
0d
Get Alerted When VRAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: VRAX is 88.6% above its trading range ($1.66). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: VRAX is 88.6% above its trading range ($1.66). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: VRAX is currently trading at $3.13, which is considered extended relative to its 30-day fair value range of $-0.41 to $1.66.
Technical Outlook: Technically, VRAX is in a downtrend. The price is approaching resistance at $0.24. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.2% recently.
Market Sentiment: VRAX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.00 (+698.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VRAX is in a downtrend. The price is approaching resistance at $0.24. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 14.2% recently.
Market Sentiment: VRAX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.00 (+698.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$-0.41 -
$1.66
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+88.6% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+14.2%)
- BULLISH: Trading 698.7% below Wall St target ($25.00)
- WARNING: Recommendation downgraded due to 88.6% overvaluation
Trading Range Analysis
30-Day Trading Range
$-0.41 -
$1.66
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.17
Resistance Level
$0.24
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.52
Wall Street Target
$25.00
(+698.7%)
Revenue Growth (YoY)
-67.5%
Share & Embed Analysis
Last updated: July 02, 2026 10:46 PM ET
Data refreshes hourly during market hours. Next update: 11:46 PM
Data refreshes hourly during market hours. Next update: 11:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
